Fig. 5.

Subgroup analysis of risk of $\ge$ 5% BW loss on AF incidence in patients with T2DM treated with SGLT2i. The benefit of BW loss associated with SGLT2i treatment in the reduction of AF risk persisted across most T2DM subgroups, regardless of underlying comorbidities, baseline BMI, or different HbA1c. Notably, SGLT2i use was associated with greater reductions in new-onset AF events in patients with normal renal function than in those with impaired renal function (P for interaction = 0.01). ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor-neprilysin inhibitor; BMI: body mass index; CHF: congestive heart failure; CVA: cerebral vascular disease; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HTN: hypertension; IHD: ischemic heart disease AF: atrial fibrillation; CI: confidence interval; eGFR: estimated glomerular filtration rate; HbA1c: glycated hemoglobin A1c; aHR: adjusted hazard ratio; SGLT2i: sodium–glucose cotransporter 2 inhibitor; T2DM: type 2 diabetes mellitus; BMI: body mass index; BW: body weight; SE: standard error; MRA: mineralocorticoid receptor antagonist; TZD: thiazolidinedione